Key Findings
- In Caris-profiled pMMR/MSS endometrial cancers treated with pembrolizumab or dostarlimab, T-cell, NK-cell, and combined T/NK immune signatures were independently associated with improved overall survival following immune checkpoint inhibition.
- This study highlights how genomic, transcriptomic, immune, and biomarker profiling can refine gynecologic cancer subgroups, inform therapeutic development, and reveal clinically relevant differences in treatment response and outcomes.